Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more

Recent & Breaking News (NDAQ:MRNS)

Marinus Pharmaceuticals Provides Pipeline Update

GlobeNewswire June 30, 2020

Marinus Pharmaceuticals to Host Pipeline Update Webinar

GlobeNewswire June 24, 2020

Marinus Pharmaceuticals to Present at SVB Leerink's CybeRx Series: 2nd Annual CNS Forum

GlobeNewswire June 22, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 16, 2020

Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and Secretary

GlobeNewswire June 15, 2020

Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire June 2, 2020

Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

GlobeNewswire May 28, 2020

Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire May 28, 2020

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

GlobeNewswire May 4, 2020

Marinus Pharmaceuticals Announces Formation of Scientific Advisory Board

GlobeNewswire April 30, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 27, 2020

Marinus Pharmaceuticals to Announce First Quarter 2020 Financial Results on Monday, May 4, 2020

GlobeNewswire April 23, 2020

Benitec Biopharma Appoints Edward Smith to the Board of Directors

PR Newswire April 14, 2020

MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

GlobeNewswire March 23, 2020

Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate Communications

GlobeNewswire March 19, 2020

Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results

GlobeNewswire March 16, 2020

Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder

GlobeNewswire February 25, 2020

Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

GlobeNewswire February 24, 2020

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 14, 2020

Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting

GlobeNewswire February 3, 2020